Shares of Biocon are in focus on Sunday, February 1, after a major policy announcement for the biopharma industry in Union Budget 2026.
While presenting the Budget, Nirmala Sitharaman said the government will allocate Rs 100 billion (Rs 10,000 crore) to the biopharma sector over the next five years. The proposed allocation signals a long-term commitment to strengthening India’s biopharmaceutical ecosystem.
The funding is expected to support areas such as research and development, manufacturing capabilities, innovation, and scale-up across the biopharma value chain. The announcement aligns with the government’s broader objective of promoting high-value manufacturing and enhancing India’s position in global pharmaceutical and biotechnology markets.
Market participants are closely tracking biopharma companies, including Biocon, as further details on the structure, eligibility criteria, and deployment of the allocated funds are expected through Budget documents and subsequent policy notifications.
More clarity is likely to emerge on how the multi-year allocation will be phased and which segments of the biopharma sector will be prioritised under the proposed framework.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
